Doseology Sciences Inc. (CSE: MOOD) (OTCQB: DOSEF) (FSE: VU70) has announced the revocation of a management cease trade order issued against the company on October 29, 2026, following the filing of its audited annual financial statements for the fiscal year ended June 30, 2026. The British Columbia Securities Commission lifted the order after the company completed its required filings on November 3, 2026. Separately, Doseology has confirmed its intention to adopt the Semi-Annual Reporting Pilot Program, reducing its interim disclosure obligations from quarterly to semi-annual going forward.

Key Points

  • Doseology Sciences Inc. (CSE: MOOD) (OTCQB: DOSEF) (FSE: VU70) is a Kelowna, British Columbia-based oral stimulant and cognitive support products company.
  • The BCSC revoked the MCTO issued October 29, 2026 after audited annual financials were filed November 3, 2026.
  • The company will no longer file interim financial statements for its three-month and nine-month periods, beginning with the period ending September 30, 2026.
  • Investors should watch whether the company maintains compliant and timely disclosure under its reduced reporting schedule.

BCSC Revokes MCTO Following Completion of Annual Financial Filings

The British Columbia Securities Commission revoked Doseology's management cease trade order on November 5, 2026, after the company filed its audited annual financial statements for the fiscal year ended June 30, 2026, together with the related management's discussion and analysis and certifications from both the Chief Executive Officer and Chief Financial Officer. Those required filings were submitted on November 3, 2026. Doseology also confirmed it is no longer listed as being in default on the BCSC's reporting issuer list or on comparable default lists in any other Canadian jurisdiction where it operates as a reporting issuer.

Doseology Adopts SAR Pilot Program Under Coordinated Blanket Order 51-933

Doseology has voluntarily elected to participate in the Semi-Annual Reporting Pilot Program established under Coordinated Blanket Order 51-933, which allows eligible venture issuers listed on the Canadian Securities Exchange or TSX Venture Exchange to transition from quarterly to semi-annual financial reporting. The company will no longer be required to prepare or file interim financial statements and related MD&A for its three-month or nine-month reporting periods. It will, however, continue filing audited annual financial statements and six-month interim financial reports, and will continue reporting all material changes as required under National Instrument 51-102.

Eligibility Criteria Confirmed for the SAR Program

Doseology states it meets all eligibility requirements for the SAR Pilot Program, including being a venture issuer with annual revenues below $10 million, maintaining a disclosure record of more than 12 months, and having filed all required periodic and timely continuous disclosure documents. Should the company discontinue participation in the pilot program at any point, the release states it will announce that decision in a future news release. The immediate share price impact of these developments was not clear from available public information.